文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

超低分割与中度低分割图像引导前列腺放疗联合HDR近距离治疗推量的四年毒性与局部控制比较:一项I-II期单中心试验

Comparison of four-year toxicities and local control of ultra-hypofractionated vs moderate-hypofractionated image guided prostate radiation with HDR brachytherapy boost: A phase I-II single institution trial.
PubMed 文献 · Clin Transl Radiat Oncol · 2023-02-08

这项单臂前瞻性单中心研究纳入28例中危前列腺癌患者,接受25 Gy/5次超低分割放疗联合15 Gy HDR近距离治疗推量,并与两个历史对照组(36 Gy/12次151例、37.5 Gy/15次311例,均联合相似HDR推量)比较。中位随访48.5个月,三组间胃肠道和泌尿生殖系统毒性无显著差异,超低分割组无Phoenix标准定义的生化复发。作者认为超低分割方案在毒性和局部控制方面似乎与标准方案等效,需更大样本随机对照试验进一步确认。

要点

  • 超低分割组28例接受25 Gy/5次联合15 Gy HDR推量,中位随访48.5个月。
  • 三组间IPSS和EPIC-26胃肠道及泌尿生殖系统评分随时间无显著差异。
  • 超低分割组无Phoenix标准定义的生化复发,作者认为毒性及局部控制似乎等效。

核心结论

  • 超低分割联合HDR近距离治疗推量的方案在毒性和局部控制方面似乎与标准治疗组等效。
  • 作者指出需要更大样本的随机对照试验进一步确认该发现。

研究设计与样本

  • 单臂、前瞻性、单中心研究,实验组纳入28例中危前列腺癌患者,接受25 Gy/5次放疗联合15 Gy HDR近距离治疗推量。
  • 两个历史对照组分别接受36 Gy/12次(151例)或37.5 Gy/15次(311例)放疗联合相似HDR推量。
  • 采用国际前列腺症状评分(IPSS)和扩展前列腺癌指数综合问卷(EPIC-26)在基线和每次随访时评估结局。

主要发现

  • 实验组中位随访48.5个月,36 Gy/12次组中位随访47个月,37.5 Gy/15次组中位随访60个月。
  • IPSS和EPIC评分显示三组间胃肠道和泌尿生殖系统领域随时间无显著差异。
  • 超低分割组无Phoenix标准定义的生化复发。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出需要更大样本的随机对照试验进一步确认该发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE/OBJECTIVES: To analyze the long term efficacy and safety of an ultra-hypofractionated (UHF) radiation therapy prostate treatment regimen with HDR brachytherapy boost (BB) and compare it to moderate-hypofractionated regimens (MHF). MATERIALS/METHODS: In this single arm, prospective monocentric study, 28 patients with intermediate risk prostate cancer were recruited in an experimental treatment arm of 25 Gy in 5 fractions plus a 15 Gy HDR BB. They were then compared to two historical control groups, treated with either 36 Gy in 12 fractions or 37.5 Gy in 15 fractions with a similar HDR BB. The control groups included 151 and 311 patients respectively. Patient outcomes were reported using the International Prostate Symptom Score (IPSS) and Expanded Prostate Index Composite (EPIC-26) questionnaires at baseline and at each follow-up visit. RESULTS: Median follow-up for the experimental arm was 48.5 months compared to 47 months and 60 months compared to the 36/12 and 37,5/15 groups respectively. The IPSS and EPIC scores did not demonstrate any significant differences in the gastrointestinal or genitourinary domains between the three groups over time. No biochemical recurrence occurred in the UHF arm as defined by the Phoenix criterion. CONCLUSION: The UHF treatment scheme with HDR BB seems equivalent to standard treatment arms in terms of toxicities and local control. Randomized control trials with larger cohorts are ongoing and needed to further confirm our findings.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Beaudry MM, Carignan D, Foster W, et al. Comparison of four-year toxicities and local control of ultra-hypofractionated vs moderate-hypofractionated image guided prostate radiation with HDR brachytherapy boost: A phase I-II single institution trial. Clin Transl Radiat Oncol. 2023. PMID: 36875870. doi:10.1016/j.ctro.2023.100593

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。